Tscan Therapeutics Inc Cash Flow Reinvestment Rate
Latest as of September 2023:
7.84x
Tscan Therapeutics Inc cash flow reinvestment rate. Tscan Therapeutics Inc (TCRX) has a Cash Flow Reinvestment Rate of 7.84x as of September 2023, reinvesting $62.83 Million (capex $1.42 Million plus investments $-61.41 Million) from operating cash flow of $8.02 Million. Explore TCRX debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
7.84x
(Capex + Investments) / Operating CF
Total Reinvested
$62.83 Million
Capex + Investments
Operating Cash Flow
$8.02 Million
USD
Capital Expenditures
$1.42 Million
USD
Tscan Therapeutics Inc Cash Flow Reinvestment Rate by Year (None–None)
Tscan Therapeutics Inc cash flow reinvestment rate by year from None to None. Year-by-year capital reinvestment analysis for Tscan Therapeutics Inc. For the full cash flow conversion analysis, see cash flow conversion of Tscan Therapeutics Inc.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow